<DOC>
	<DOC>NCT00978107</DOC>
	<brief_summary>This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of 5-fluorocytosine in patients with primary or secondary hepatic tumors.</brief_summary>
	<brief_title>Trial of TG4023 Combined With Flucytosine in Liver Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Flucytosine</mesh_term>
	<criteria>Patients with advanced disease without any other standard of care treatment options: hepatic metastases of colorectal cancer (CRC) or of other cancers Hepatocellular carcinoma (HCC) At least one unresectable target tumor located in the liver, measuring 25 cm and accessible to IT administration of TG4023 and amenable to radiological measurement using RECIST, Weight ≤ 100 kg, Patients with stable disease, who have to discontinue chemotherapy because of intolerance, ECOG performance status ≤ 2, Life expectancy ≥ 3 months, Hematology: Absolute neutrophil count &gt; 1,500/mm3, Hemoglobin &gt; 9g/dL, Platelet count &gt; 100,000/mm3, Prothrombin time international normalized ratio (INR) ≤ 2; partial thromboplastin time ≤ 1.66 times upper limit of normal (ULN), Biochemistry: Total bilirubin ≤ 3 x ULN, Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase 5.0 x ULN, Creatinin clearance ≥ 40 mL/min, Total albumin ≥ 30 g/L, Antivitamin K anticoagulants should have been switched for lowmolecular weight heparin prior to TG4023 injection, Signed, written Independent Ethics Committee (IEC)approved informed consent. ChildPugh stage C hepatic insufficiency, Impaired renal function (creatinin clearance &lt; 40 mL/min), Known deficiency in dihydropyrimidine dehydrogenase (DPD) or total DPD deficiency diagnosed at baseline in those patients not previously treated with 5FUrelated compounds, Ascites, Brain metastases, Significant impairment of gastrointestinal (GI) tract absorption capacity, such as total gastrectomy, gastric mucosal atrophy, extensive intestinal resections or malabsorption disease will not be treated by oral 5FC, History of bleeding disorders, Pregnant or breastfeeding women, Human Immunodeficiency Virus (HIV) positive, Chronic use of immunodepressants within 4 weeks prior to TG4023 injection or immunedepressed patients, Hypersensitivity to 5FC, Hypersensitivity to egg proteins, Concomitant or previous chemotherapy or targeted therapy within 4 weeks prior to TG4023 injection and last treatment with bevacizumab (Avastin®) within 2 months prior to TG4023 injection, Concomitant treatment with antiinflammatory drugs: systemic corticosteroids and nonsteroidal antiinflammatory drugs (NSAIDs), Prior gene therapy, Prior participation in any other research protocol involving an IMP within 2 months prior to TG4023 injection, Major surgery within 6 weeks of TG4023 injection,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Hepatic tumors</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
</DOC>